RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.
26 Sep, 2021 | 21:43h | UTCCommentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post
Commentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post